Focal Interest
Focal Interest

Acquired resistance

  1. Talazoparib resistance in triple-negative breast cancer linked to BRN2 and SHLD2
    Study identifies BRN2-mediated and SHLD2-related resistance to talazoparib in BRCA-mutant breast cancer, proposing combination therapy approaches to improve neoadjuvant treatment outcomes.